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Abstract 
Introduction. Geldanamycin (GA) is an ansamycin antibiotic that exhibits potent anti-neoplastic 
properties. The aim of this study was to assess the impact of GA and its derivatives on the growth 
and invasiveness of myeloma cell lines and CD138+ cells derived from the bone marrow of patients 
with multiple myeloma.  
Materials and methods. We evaluated cell proliferation, survival, apoptosis, cell cycle of my-
eloma cells, and the expression of cell surface proteins after incubation with geldanamycin or its 
derivatives.  
Results. GA and its analogs have an effect on myeloma cells by inhibiting their growth in a time and 
dose-dependent manner. Myeloma cell lines demonstrated decreased proliferation after incuba-
tion with 10 nM of GA or 100 nM GA analogs. The first significant effects of GA on U266 cells was 
observed after 24 hours. After 24 hours, U266 cells incubated with 100 nM GA were in both early 
and late stages of apoptosis; 17AEP and 17DMAG caused apoptosis of similar intensity to GA. It 
has been observed that GA and its derivatives cause caspase-3 activation. Analysis of the activity of 
AKT and MAP 42/44 kinases was performed by incubating U266 cells for 24 and 48 hours in100 nM 
of GA and its derivatives. After 24 hours incubation, no significant changes in protein expression 
were observed, while after 48 hours, the strongest changes were seen in AKT protein expression 
after incubation with GA and 17AEP-GA. In studies of the cell cycle, it was found that 100 nM 
17AEP-GA and 17-DMAP-GA cause cell cycle abnormalities. We observed a nearly two-fold in-
crease in U266 cells in the G1 phase and a simultaneous decrease in the percentage of cells in the 
G2/M phase, indicating that cells were halted in the G1 phase. In the case of the INA6 cells, pro-
liferation was halted in both the G1 and G2/M phases.  
Conclusions. GA and the analogues that we tested can inhibit myeloma cell growth by induction 
of apoptosis and blockage of cell cycle progression, and have an effect on the down-regulation of 
the MET receptor. The GA derivatives tested, despite their modifications still retain strong an-
ticancer properties. Specifically, two analogues of GA, 17AEP-GA and 17DMAG due to their 
properties can be more effective and safer chemotherapeutic agents than 17AAG, which is cur-
rently used and described in literature. 
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Introduction 
Multiple myeloma (MM) is a malignant prolif-
eration of plasma cells producing and secreting 
monoclonal immunoglobulins or light chains thereof. 
Among all malignant tumors, the incidence of MM is 
1-2%, which represents approximately 15% of hema-
topoietic tumors [1]. The most characteristic symp-
toms include the following: clearly marked multiple 
osteolytic foci in the bones accompanied by pain and 
pathological fractures, renal failure, anemia, and sus-
ceptibility to infection. The introduction of new drugs 
in the past decade to treat MM has doubled median 
survival of patients, which is currently 6-7 years. 
Ongoing research into new therapeutic agents raises 
hopes of a greater increase in survival. Current re-
search is targeted not only at drugs which effect the 
myeloma cells themselves but also at other factors that 
affect the interactions of these cells with the bone 
marrow (BM) stroma [2,3]. 
Heat shock protein 90 (HSP90) comprises about 
1-2% of all cellular proteins. This protein plays an 
important role in maintaining homeostasis in both 
physiological and stress conditions. HSP90 is a con-
served protein responsible for the correct folding of 
proteins and stabilization of their structure. It is se-
creted in response to stress (infectious agents, tem-
perature, heavy metals, acidification) and is involved 
in intracellular signaling [4]. HSP90 cooperates with 
other proteins by forming complexes with them to 
maintain the active form of the target proteins and 
direct them to a degradation pathway if they are ab-
normally conformed [4]. Cancer cells appear to be 
especially dependent on HSP90 activity. In neoplastic 
cells abnormal HSP90 complexes are present which 
stabilize mutated forms of proteins, via strong bind-
ing to carrier proteins, thus avoiding degradation [4]. 
HSP90 are produced in excess and mutate assuming 
an unstable form. HSP90 target proteins regulate a 
number of processes determining the growth and 
spread of cancer cells, specifically factors: stimulating 
angiogenesis (factor-1 induced by hypoxia HIF1α, 
MET, Src, vascular endothelial growth factor VEGF), 
cell cycle control (CDK4, CDK6, cyclin D), inhibition 
of apoptosis (AKT, insulin-like growth factor 1 re-
ceptor IGF-1R), survival and invasiveness (matrix 
metalloproteinase-2 MMP-2 and urokinase-2 ) [5]. The 
role of HSP90 in cancer cells is to maintain homeosta-
sis, despite unfavorable conditions (hypoxia, malnu-
trition) and intensive production of abnormal proteins 
[6]. It is therefore hypothesized that the level of 
chaperone proteins in cancer cells may correlate with 
the degree of their malignancy. Increased activity of 
HSP90 was noted in a variety of tumors [7, 8], hence 
the use of inhibitors of HSP90 as a trial in the treat-
ment of proliferative diseases [4, 9].  
Geldanamycin (GA), belongs to the ansamycin 
antibiotic subclass, and was first isolated in 1970 in 
actinomycete culture of Streptomyces hygroscopicus. 
In 1993, Whitesell et al found that GA specifically in-
hibits the formation of complexes of HSP90-v-SRC, 
suggesting HSP90 has an important role in the process 
of malignant transformation [10]. Further studies 
have shown that GA also downregulates a number of 
other proteins involved in tumorogenesis, such as 
mutant p53, mutant B-RAF, AKT, BCR-ABL, and 
ERBB2 [11]. GA’s anti-tumor effect results from sev-
eral mechanisms including: inhibition of the prolifer-
ative effect of proteins such as RAF-1, a reduction in 
expression of the mutant or overproduced oncogenic 
proteins, inhibition of proteins determining neoplastic 
cell survival such as AKT, blocking the cell cycle, in-
hibition of angiogenesis, and the reduction of inva-
siveness and the ability to metastasize [12]. 
The aim of this study was to assess the impact of 
GA and its derivatives on the growth and invasive-
ness of myeloma cell lines and CD138+ cells derived 
from the BM of patients with MM. 
Materials and methods 
Patients 
BM samples were collected from 20 patients with 
MM, including 12 men and 8 women, with age rang-
ing from 45 to 78 years (average 61.5 years), and with 
marrow plasmacytosis from 15% to 65% (average 
35.6%). Patients were treated at the Hematological 
Clinic of the University Hospital in Krakow. Addi-
tionally, samples were obtained from 10 volunteers, 
including 5 men and 5 women, with age ranging from 
48 to 68 years (average 60.5 years). Diagnosis of MM 
was based on histological increase of myeloid cells on 
BM biopsy and monoclonal hyperglobulinemia. BM 
was collected by aspiration from the posterior iliac 
crest into a sterile Vacutainer tube (Becton Dickinson) 
with anticoagulant (EDTA or heparin). Informed 
consent was obtained from all the participants, and 
the study was approved by the local ethics committee.  
Isolation and culture of primary myeloma cells 
Primary myeloma cells were isolated from fresh 
BM aspirates of MM patients. BM mononuclear cells 
were separated by centrifuging the total aspirate on a 
Ficoll gradient (1000 x g, 30 min), followed by incu-
bating (15 min, 4°C) with anti-CD138+-coupled mag-
netic beads, and then isolating the cells using the 
MiniMACS system (Miltenyi, Biotec, Auburn, CA, 
USA). Isolated cells were cultured in the presence of 
10% fetal bovine serum (FBS) and 2 ng/ml IL-6. Purity 
of isolated cells was verified by flow cytometry (FACS 
Canto, Becton Dickinson, Germany) using monoclo-
nal anti-phycoerythrin (PE) labeled CD138+ (BD 
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PharMingen, San Diego, USA).  
Isolation and culture of normal cells 
The study used mesenchymal stem cells (MSC) 
derived from the BM of healthy donors (BM-MSC) 
and patients with MM (MMBM-MSC). BM-MSC were 
isolated from BM of healthy donors or patients with 
MM using the protocol described by Friedenstein et 
al. [13], using the fraction of BM mononuclear cells, 
obtained by centrifugation of the total BM on Ficoll 
gradient (1000 x g, 30 min), and then selecting MSC by 
adhesion to a plastic surface. Mononuclear cells were 
seeded on plastic bottles (Sarstedt AG & Co., Ger-
many) at a concentration of 4 x 105/cm2. Culture of 
BM-MSC and MMBM-MSC was carried out on Dul-
becco's modified eagle's medium (DMEM) (Sig-
ma-Aldrich) and supplemented with 10% FBS, for 
incubation of MSC (Stem Cell Technologies) supple-
mented with an antibiotic (PAA Laboratories GmbH) 
at 37°C in an atmosphere of 5% CO2 and 95% humid-
ity. After reaching 90% density, the cells were pas-
saged using 0.05% trypsin (trypsin-EDTA, PAA La-
boratories GmbH) and were seeded at a concentration 
of 1 x 104/cm2 into new culture flasks.  
Breeding myeloma cell lines 
Myeloma cell lines were cultured using RPMI 
1640 medium (Gibco BRL, Grand Island, NY, USA) 
and supplemented with FBS (PAA Laboratories, 
Pasching, Austria), 2 mM L-glutamine and the fol-
lowing antibiotics: 100 IU/ml penicillin and 10 ug/ml 
streptomycin (Gibco BRL, Grand Island, NY, USA) at 
37 ° C in an atmosphere of 5% CO2 and 95% humidity. 
Cell lines were passaged two times a week. Names 
and myeloma line culture conditions are shown in 
Table 1. 
 
 
Table 1. Names and culture conditions of myeloma cell lines 
Line %FBS IL-6 (ng/ml) 
U226 15 - 
RPMI 20 - 
INA6 10 2 
CAG 10 - 
 
 
Geldanamycin 
Geldanamycin, 17-Allylamino-17-demethoxy-
geldanamycin (17AAG), 17-(Dimethylaminoe-
thylamino)-17-demethoxygeldanamycin (17DMAG), 
17-[2-(Pyrrolidin-1-yl)ethyl] aminno-17-demetho-
xygeldanamycin(17AEP-GA), and 17-(Dimethylami-
nopropylamino)-17-demethoxygeldanamycin 
(17DMAP-GA) were purchased at Invivogen (San 
Diego, CA, USA). GA and 17AAG were dissolved in 
DMSO (Merck, Darmstadt, Germany) while 
17DMAG, 17AEP-GA, and 17DMAP-GA were dis-
solved in water. 
Measuring the proliferation/survival of 
myeloma cells using MTS assay 
U266, RPMI, and CAG cell lines were plated in 
complete RPMI medium to 96 well culture plates 
(1x103/well), followed by addition of GA at concen-
trations of 1, 10, 100, 500, and 1000 nM, at 24, 48, 72, 
and 96 hours after inhibitor exposure. Evaluation of 
cell survival was performed using a colorimetric MTS 
assay (Cell Titer 96 Aqueous One Solution Cell Pro-
liferation Assay, Promega, Madison, WI, USA). Te-
trazolium salt (MTS), as a result of redox activity of 
mitochondria, is reduced to colored formazan. The 
resulting colored product, reflecting the number of 
metabolically active cells was assessed using a EL800 
reader (BIO -TEK Instruments, USA) at a wave length 
of 490 nm. The results are shown as a percent of con-
trol, where the GA untreated cells were used as con-
trol. There were three independent experiments.  
Detection of apoptosis 
Apoptosis was assessed using annexin V binding 
assay with simultaneous use of propidium iodide (PI). 
Annexin V binds to phosphatidyl serine, which is 
present on the surface of apoptotic cells. Propidium 
iodide enters the cells due to loss of membrane integ-
rity and thus stains necrotic cells or cells in the late 
stages of apoptosis. Cells were washed with cold 
Phosphate Buffered Saline (PBS). Cell pellets were 
resuspended in 100μl of binding buffer (Becton Dick-
inson Pharmingen, San Diego, CA, USA), then 5 ml of 
phycoerythrin-labeled annexin V and 10 ml of PI were 
added (Pharmingen Becton Dickinson). After 15 
minutes of incubation at room temperature, 400 ml of 
binding buffer was added and the solution was ana-
lyzed using a FacsCanto flow cytometer (Becton 
Dickinson, San Jose, CA, USA). Analysis of the results 
was performed using the Facs Diva (Becton Dickin-
son). 
Cell Cycle Analysis 
An analysis was performed of the cell cycle after 
48 hours of incubation with GA and its derivatives. 
Distribution of the number of cells in the different cell 
cycle phases were assessed by measuring DNA con-
tent using fluorescent labeled propidium iodide. 
Samples for flow cytometry analysis were prepared 
by fusing the cells in 75% aqueous ethanol solution 
and incubating for at least 12 hours at 40°C. The sam-
ples were then digested with RNase [50 ug/ml] (ICN 
Polfa, Rzeszów, Poland) for 30 min at 37°C, and then 
incubated with PI [50 ug/ml] (Sigma), and diluted in 
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a sodium citrate solution (Sigma) for 30 min at room 
temperature. The analysis was performed using a Facs 
Canto flow cytometer (Becton Dickinson). Analysis of 
the results was performed using the Facs Diva pro-
gram. 
Evaluation of Protein Expression 
Western Blot was used to determine the expres-
sion of protein in conjunction with immunohisto-
chemical staining and histological preparations. 
Determination of protein concentration 
Cells were lysed on ice for 10 minutes using 
M-PER buffer (Pierce, Rockford, IL, USA) supple-
mented with phosphatase and proteinase inhibitors as 
follows: 10 mg/ml aprotinin, 1 mg/ml pepstatin A, 10 
mg/ml leupeptin, 1 M NaF, 10 mM sodium pyruvate, 
500 mM EDTA, and 10 mg/ml PMSF (Sigma). Con-
centration measurement was performed by the Brad-
ford method using Bio-Rad reagent protein assay 
(Bio-Rad, Hercules, CA, USA) and an EL800 reader. 
The protein concentration in the samples was deter-
mined on the basis of a calibration curve on which 
albumin was used as the standard. 
Evaluation of protein expression by Western 
blot 
Isolated protein was denatured in the presence 
of Bond-Braker (Pierce) and loading buffer (NuPage 
LDS Sample Buffer, Invitrogen) for 10 minutes at 
70°C. Prepared samples containing 10 mg of protein 
were loaded and separated on a polyacrylamide gel 
with 10% SDS (SDS-PAGE) at a voltage of 150 V for 
100 min. The next step was to transfer the sample to 
PVDF nitrocellulose membrane (BioRad) at 100 V for 
60 min. We used Precision Protein Standard (BioRad) 
as a size marker. The presence of proteins including 
MET, AKT, MAP, and HSP90 was detected using 
rabbit monoclonal anti-MET (Santa Cruz Biotech, 
Santa Cruz, CA, USA), anti-AKT, anti-MAP and an-
ti-HSP90 (Cell Signaling, Danvers, MA, USA) anti-
bodies. As secondary antibodies, anti-rabbit IgG was 
used as well as related anti-mouse Horse Radish Pe-
roxidase (HRP) (Santa Cruz Biotech). The number of 
separated products was controlled using rabbit an-
ti-GAPDH (Santa Cruz Biotech). The phosphorylation 
of p44/42 MAPK kinase (Tyr204/Thr202) and AKT 
(Ser473) was studied using a mouse monoclonal an-
tibody against phosphorylated p44/42 MAPK, and 
rabbit antibodies against the AKT kinase (Cell Sig-
naling). Mouse anti-IgG and rabbit anti-HRP-linked 
antibodies were used as secondary antibodies. The 
number of separated products was controlled using 
rabbit anti-GAPDH (Santa Cruz Biotech). After the 
standard washing conditions, vinyl membrane 
(PVDF) were coated with a chemiluminescent sub-
strate for HRP (ECL reagent, Amersham Life Sci., Lit-
tre Chalfont, UK) and exposed to photographic film 
(Hyper Film ECL, Amersham Life Sci.). 
RNA isolation and reverse transcription 
reaction 
RNA was isolated using RNeasy Mini Kit (Qi-
agen, Valencia, CA, USA). The concentration and pu-
rity of the RNA obtained was evaluated by measuring 
the absorbance at a wavelength of 260nm and 280nm 
using a DU 640B spectrophotometer (Beckman Coul-
ter, Fullerton, CA, USA). RNA was transcribed into 
cDNA using MMLV reverse transcriptase (Promega) 
and random primers (Promega). 
PCR reaction in real time 
Evaluation of gene expression was performed by 
quantitative PCR in real time (qRT-PCR) based on 
specific TaqMan probes (Applied Biosystems, Foster 
City, CA, USA) using an ABI PRISM 7300 Sequence 
Detection System (Applied Biosystems). The reaction 
mixture contained the ingredients set forth in Table 2. 
A list of probes used in the experiments is included as 
Table 3. Figure 1 is a diagram of the qRT PCR reaction. 
 
Table 2. Composition of ingredients used in the qRT-PCR reac-
tion 
TaqMan PCR Master Mix 25μl 
cDNA 100ng 
20x probe 2.5μl 
Water To final volume of 50μl 
 
Table 3. Probes used for qRT PCR 
TaqMan Probe Number (Applied Biosystems) 
MET Hs01565589_ml 
HSP90 Hs00743767_ml 
GAPDH Hs99999905_ml 
 
 
 
 
Figure 1. The qRT PCR reaction 
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To calculate results, we used a method of ana-
lyzing the relative gene expression - ΔΔCt, which is 
based on comparison of Ct of the tested and reference 
gene. 
Statistical Analysis 
Statistical analysis of results was performed us-
ing Microsoft Excel and GraphPad Prism 4.02. Ex-
periments were carried out at least 3 times. Quantita-
tive results are presented in graphs or tables, and are 
expressed as mean with an error indicating the 
standard deviation or standard error. The captions 
under the graphs show the number of times the ex-
periments were carried out and the size of the sample 
in a single experiment. The statistical significance of 
differences between groups was tested using Student 
t test or one-way analysis of variance at a significance 
level of 0.05. 
Results 
GA and its derivatives inhibit the growth of 
myeloma cell line 
Blocking of HSP90 can affect many cellular pro-
cesses, including growth. To determine the effect of 
GA on the growth of the U266, RPMI, INA6, and CAG 
myeloma cell lines, MTS assay was performed. It was 
found that GA its and analogs impair the myeloma 
cells by inhibiting their growth in a time and dose 
dependent manner (Fig. 2). It was also observed that 
the effect of GA and its different analogs varies de-
pending on the myeloma line (Fig. 3). Myeloma cell 
lines showed inhibition of proliferation after admin-
istration of 10 nM of GA and 100 nM of GA analogs. 
We also examined whether the effect of GA and ana-
logues on myeloma cells is dependent on length of 
exposure. It was observed that inhibition of prolifera-
tion was greater with longer exposure to the inhibitor. 
The first significant effects of GA on U266 cells was 
observed after 24 hours incubation with a 10 nM dose 
of GA or a 100nM dose of GA analogs. The inhibition 
of growth of U266 proceeded with the length of in-
cubation with the inhibitor. Similar effects of GA and 
its analogs was observed in the other myeloma cell 
lines (RPMI and CAG). We chose the U266 line and a 
100nM dose of GA analogs for further experimenta-
tion. 
GA and its derivatives induce apoptosis of 
myeloma cell line 
Inhibition of cell growth may be due to induction 
of apoptosis and cell cycle arrest, among other 
mechanisms. Using annexin V and propidium iodide 
staining, we examined whether GA induces apoptosis 
of myeloma cells. 24 hour incubation of U266 cells 
with 100 nM GA resulted in the emergence of cell 
populations at both early (annexin V-binding cells, 
negative for propidium iodide incorporation) and late 
stages of apoptosis (annexin V-binding cells, positive 
for propidium iodide ) (Fig. 4). 
 
 
Figure 2. Effects of GA and analogues on MM line U266 at 24, 48, 
72, and 96 hours incubation. p<0.001 compared to the control for GA 
and its analogues and at all time points for concentrations of 100, 500, and 
100 nM. 
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Figure 3. Effects of GA and its analogues on the RPMI (A), U266 (B), and CAG (C) MM cell lines after 96 hours of incubation. 
* p<0.005.  
 
Figure 4. Effects of GA and analogues on apoptosis of myeloma cells. The effect of 24 hours of incubation with 100 nM GA and its analogues on 
apoptosis of the U266 MM line. Exemplary graphs selected from three independent experiments.  
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48 hours exposure to 100nM of GA and its ana-
logs caused increased apoptosis, thus increasing the 
percentage of annexin V-binding cells. In order to 
compare the sensitivity of the myeloma cell lines both 
dependent and independent of IL-6, analogous ex-
periments were carried out on the U266 and INA6 cell 
lines. The results are shown in Table 4. 
 
Table 4. Effect of GA on apoptosis of myeloma 
cells-binding of annexin V. The increase in annexin V binding 
cells relative to the control after 24 and 48 hours exposure to a 
100 nM dose of GA and its derivatives. Results are from three 
independent experiments. 
 U266 INA6 
 24 hours 48 hours 24 hours 48 hours 
GA + ++ + +++ 
17AEP-GA + ++ + +++ 
17DMAP-GA + + + ++ 
17AAG + + + ++ 
17DMAG + ++ + +++ 
The following convention was used for this experiment: 
+ Up to 30% apoptotic cells 
++ Up to 50% apoptotic cells 
+++Greater than 50% apoptotic cells 
 
 
17AEP-GA and 17DMAG cause a similar level of 
apoptosis when compared to GA. The U266 line 
proved to be less sensitive to GA analogues than 
INA6 dependent IL6. Both 17DMAP -GA and 17AAG 
showed weak proapoptotic activity in the U266 and 
INA6 cell lines. 
The process of programmed cell death is carried 
out by activation of proteolytic enzymes - caspases, 
which irreversibly digest numerous cytoplasmic and 
nuclear proteins. In our experiments we examined 
whether GA and its derivatives result in activation of 
caspase-3. It has been previously observed that GA 
and its derivatives cause caspase-3 activation (Fig. 5). 
The highest percentage of cells displaying examined 
features of apoptosis, was observed after 48 hours 
incubation with GA, 17AEP-GA, and 17DMAG. 
 
 
 
 
Figure 5. Effects of GA and its derivatives on the activity of 
Caspase-3 in U266 cells. Increase in the number of cells with activated 
caspase -3 relative to the control after 48 hours exposure to a 100 nM 
dose of GA and its derivatives. Results are from two independent ex-
periments. 
 
GA and its derivatives induce apoptosis of 
myeloma cells harvested from patients 
CD138+ cells isolated from the BM of patients 
with MM were analyzed for level of apoptosis. 3 in-
dependent experiments were performed. The results 
of the experiments show the greatest percentage of 
cells displaying apoptotic features after 48 hours of 
incubation with GA and 17DMAG (Fig. 6). 
 
 
Figure 6. Effect of GA on apoptosis of myeloma cells-binding of 
annexin V. The increase in annexin V binding cells relative to control after 
48 hours exposure to 100 nM dose of GA and its derivatives. Results are 
from analysis of three independent patients. 
 
GA and its derivatives decrease the expression 
of AKT protein 
Among the many cellular proteins, regulatory 
proteins play a very important role in the regulation 
of the controlled process of death. Three independent 
experiments were conducted examining the levels of 
AKT kinase, one of the key proteins that control the 
process of apoptosis, and MAP 42/44 which has an 
influence on gene expression, cellular division, cellu-
lar differentiation, cellular movement, and apoptosis. 
Analysis of the activity of AKT kinase and MAP 42/44 
were made by incubating U266 cells for 24 and 48 
hours with 100 nM of GA and its derivatives. After 24 
hours incubation, there were no significant changes in 
protein expression (data not shown), while after 48 
hours the strongest effects was seen in expression of 
the AKT protein when incubated with GA or 
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17AEP-GA (Fig. 7). The strongest effects were ob-
served after incubation with GA, 17AEP-GA, and 
17DMAG. 
 
 
Figure 7. Effects of GA and its derivatives on the expression of 
AKT and MAP. 1-control, 2-GA, 3-17AEP-GA, 4-17DMAP-GA, 
5-17AAG, 6-17DMAG.GAPDH-control constitutive protein. 
 
GA and its derivatives cause cell cycle 
inhibition in myeloma cells 
Inhibition of cell growth may also be due to in-
hibition of the cell cycle. It was found that 100 nM 
17AE -GA and 17-DMAP-GA causes abnormalities in 
the cell cycle. The U266 cells were observed in G1 
phase lock, which is manifested by a nearly two-fold 
increase in the percentage of cells in this phase of the 
cycle and the simultaneous lowering of the percent-
age of cells in G2/M. In the case of the INA6 line, in-
hibition of the cell cycle occurred in the G1 and G2/M 
phases. Incubation with GA resulted in an increase in 
the percentage of cells in G1 phase by about 15%, 
similar to the percentage of cells in the G2/M phase, 
whereas the number of cells in S phase decreased. A 
similar mechanism was observed in the case of GA 
derivatives, the effect with 17AEP-GA and 17DMAG 
showing the strongest effects. (Fig. 8). 
HSP90 expression in the cells of MM is higher 
than in normal cells 
Given that normal cells and neoplastic cells ex-
hibit different sensitivity to the GA and its deriva-
tives, we examined whether this phenomenon may be 
due to differences in the expression of HSP90. mRNA 
and proteins were isolated from the MSC cells and 
MM cells obtained from MM patients. Real-time PCR 
was used to test the expression of mRNA for HSP90. 
The amount of HSP90 protein in normal cells and 
cancer cells were compared using the Western Blot 
technique. It has been observed that cancer cells have 
higher expression of HSP90 as compared to normal 
cells at both the mRNA and protein levels (Fig. 9). 
 
 
 
Figure 8. Effects of GA and its derivatives on the cell cycle of MM. Panel A- U266 line, panel B-INA6 line (selected representative experiments) 
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Figure 9. HSP90 expression in normal and malignant cells 
A-HSP90 mRNA expression, B-HSP90 protein expression. * p<0.05 
compared with the level of HSP90 in normal cells. In the case of normal 
cells, four samples are included (n=4), while in the case of myeloma cells, 7 
samples are included (n=7). 
 
GA and its derivatives reduce MET receptor 
expression in myeloma cells 
The MET receptor interacts with HSP90. We 
therefore examined whether HSP90 inhibitors affect 
the MET receptor expression in myeloma cells. After 
48 hours incubation with GA and analogues, the level 
of MET protein was analyzed by Western blot. It was 
found that geldanamycin decreases the expression of 
the MET receptor in the U266 (Fig. 10). 
 
 
 
Figure 10. Effects of GA and its derivatives on MET protein 
expression in myeloma cells. 1-control, 2-GA, 3-17DMAP-GA, 
4-17DMAG, 5-17AAG,6-17AEP-GA. 
 
Discussions 
GA inhibits the growth of myeloma cells 
The anti-tumor effect of GA is primarily due to 
inhibition of the activity of proteins that promote cell 
proliferation, such as RAF-1. Additional factors in-
clude: reduction in expression of mutant or exces-
sively produced oncogenic proteins, inhibition of the 
activity of regulatory cell survival proteins, such as 
AKT, inhibition of the cell cycle, inhibition of angio-
genesis and reduction of invasiveness metastatic abil-
ity of neoplastic cells [14-18]. In recent years, studies 
have also demonstrated positive effects of GA when 
used with other compounds. Parthenolide enhanced 
geldanamycin-induced changes in apoptosis-related 
protein levels in ovarian carcinoma cell lines [19]. Wu 
et al., suggested GA enhances Fisetin induced cyto-
toxicity via induction of apoptosis in human colonic 
cancer cells [20]. The present study examined the im-
pact of GA on the proliferation of MM cells, cell 
apoptosis, cell cycle, and the expression of AKT ki-
nase and the oncogene MET. Previous reports have 
indicated different sensitivities to GA activity in vitro 
in a variety of cancers. For glioma cell lines, IC50 (50 
% growth inhibition) was estimated at 0.4-3 nM, 
breast cancer lines reported IC50 at 2-20 nM, small cell 
lung cancer lines at 50-100 nM, ovarian cancer lines at 
2000 nM, and in the case of T-cell leukemia lines be-
tween 10-700 nM [21-24]. The biological effect that GA 
has covers a wide range of intracellular pathways 
controlled by HSP90. Tumor cells exhibit diverse ge-
netic variation, which results in binding to a different 
protein profile, and this may affect the susceptibility 
of these cells to GA [25]. In our study we found that 
GA inhibits the proliferation of myeloma cells. It has 
been shown that the tested myeloma cell lines show 
varying sensitivity to GA. The selected concentration 
of 100 nM for U266 line does not deviate from the 
range of dose values determined for GA for other cell 
lines. 
Genetic variability of cancer cells may not only 
lead to varying degrees of sensitivity to the GA, but 
also result in different biological effects [25]. It was 
shown that GA can induce cell cycle arrest at different 
stages [14], as well as induce apoptosis or cell differ-
entiation [26]. We demonstrated that 24 hour incuba-
tion with GA causes earlier signs of apoptosis such as 
membrane dissymmetry in MM cells. Intracellular 
proteolytic enzymes, caspases, mobilize apoptosis. It 
has been found that GA activates caspase-3 in MM 
cells. This activation of caspase-3 leads to apoptotic 
death, as evidenced in leukemia cells. 
GA, through its interactions with HSP90 and ubiqui-
tin, initiates the degradation of many cellular pro-
teins, such as AKT, RAF-1, or CDK-4 [27]. As in the 
case of the osteosarcoma or neuroblastoma cell lines 
[16,28], we demonstrated that GA significantly de-
creases the expression AKT protein in the MM U266 
cell line. AKT kinase is a protein that controls the 
process of programmed cell death. AKT kinase acti-
vation leads to the induction of both anti-apoptotic 
factors such as NF-kB and inhibition of proapoptotic 
factors such as BAD [29]. Reducing the expression of 
AKT disrupts the balance of signals that control cell 
survival and consequently can lead to apoptosis. 
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Thus, it seems that one reason for GA-dependent 
apoptosis of myeloma cells, may be a reduction in the 
expression of AKT protein. 
Another manifestation of GA activity is cell cycle 
arrest, wherein the locking mechanism depends on 
the type of tumor, and very often even the type of cell 
line. A G2/M phase lock is frequently observed, 
causing accumulation of cells in this phase due to the 
inability to complete mitosis [30, 31]. G1 phase locking 
is less common [32]. Srethapakdi et al. showed that in 
breast cancer cell lines, the occurrence of locking in 
the G1 phase, caused by inhibition of HSP90 proteins, 
correlate with the presence of functional RB protein 
[32]. In our study we noted that inhibition of the cell 
cycle occurred in MM cells, but the mechanism of this 
phenomenon seems to be different for different cells. 
In the case of the U266 cell line, accumulation was 
observed in the G1 phase, whereas in the case of the 
INA6 cell line, we also noted lock in the G2/M phase. 
It is possible that this phenomenon is due to genetic 
differences between the cells. 
The MET receptor is one of the target proteins of 
HSP90 [27]. Webb et al demonstrated that GA reduces 
the MET receptor expression in tumor cells, thereby 
causing inhibition of HGF-dependent urokinase-type 
plasminogen activator [18]. Plasmin activation disor-
ders can lead to impairment of the maturation process 
of the extracellular matrix, and thereby limit the abil-
ity of tumor cells to metastasize. Lowering the MET 
receptor expression may also affect the inhibition of 
tumor cell migration as demonstrated in the example 
of small cell lung cancer [23]. In our study, 100 nM of 
GA resulted in a reduction of MET protein expression 
in U266 cells. 
GA derivatives have similar effects on MM cells 
as GA 
Although encouraging results have been ob-
tained in vitro, animal models of GA show GA to be 
toxic, particularly to hepatocytes [33]. One reason for 
this may be the presence of a methoxy group at the 17 
carbon of the benzoquinone ring. As this group does 
not interact with the protein HSP90, many modifica-
tions may be made within the substituent [34]. 
17AAG, one of the first GA analogues, has proved to 
be significantly less toxic while maintaining its 
antineoplastic traits and is now undergoing many 
clinical trials [35]. Shulte et al. have shown that GA 
and 17AAG not only have similar biological proper-
ties, but they also have comparable antitumor activity 
[35]. Enthusiasm for potential clinical applications of 
17AAG have been weakened because the compound 
is insoluble in aqueous solutions. Another intensively 
studied GA analogue is 17DMAG, which appears to 
have all the advantages of 17AAG, and the additional 
benefit of excellent solubility in water. Smith et al 
have demonstrated that 17DMAG is on average 3 
times more potent than 17AAG in the inhibition and 
proliferation of various tumor cell types, including 
melanoma, bladder cancer, colon cancer, pancreatic 
cancer, lung cancer, prostate cancer, and breast cancer 
[36]. In our experiments, we compared GA and its 
derivatives 17AAG and 17DMAG, already in phase I 
and phase II clinical trials, as well as 17AEP-GA and 
17DMAP-GA [37]. We examined whether GA deriva-
tives, despite their modifications, retain their anti-
tumor properties in MM cells. It was found that the 
GA derivatives we tested do in fact inhibit the growth 
of MM cells and their effect increases with the length 
of exposure. As in the case of GA, analogs initiate 
apoptosis, resulting in the activation of caspase-3, 
among other proteins. We also observed a decrease in 
the expression of the anti-apoptotic protein AKT. 
Moreover, GA derivatives caused blockade of the cell 
cycle. This effect was confirmed by examining the 
expression of MET protein derivatives. On the basis of 
the above observations, we concluded that the 
mechanism of action of GA and its derivatives is sim-
ilar. In the case of U266 cells, significant differences 
were demonstrated in the susceptibility of these cells 
to GA and its derivatives. On the basis of the MTS 
assay, it was concluded that 17DMAG, 17AEP –GA, 
and 17DMAP-GA have similar anticancer properties 
as GA. 
Although it was found that GA derivatives bind 
to HSP90 with differing affinities, a correlation be-
tween this fact and the ability to inhibit tumor cell 
growth has not been established. It is possible that the 
differing effects of the tested inhibitors result from 
their ability to penetrate into the cell [34]. The differ-
ences in the inhibition of MM cell growth, depending 
on the inhibitor used, were also reflected in the inten-
sity of phenomena such as apoptosis and cell cycle 
blockade. There have also been differences in the ac-
tion of inhibitors on protein expression of AKT and 
MET. Based on our studies in vitro, it can be con-
cluded that 17AEP-GA and 17DMAG are effective 
inhibitors of HSP90 with properties comparable to 
GA. 17AAG, in contrast, appears to be the least effec-
tive inhibitor of the growth of MM cells. 
Studies of apoptosis were also performed on 
cells derived from patients with myeloma, and after 
48 hours of incubation, the largest percentage of 
apoptotic cells was observed after application of GA 
and 17DMAG. 
To eliminate adverse effects on normal cells, we 
also compared the level of target proteins for GA and 
analogs in normal and malignant cells derived from 
patients with MM. The difference in HSP90 protein 
and mRNA levels confirmed that normal and malig-
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nant cells respond differently to GA. 
In conclusion GA and its tested analogues inhibit 
the growth of MM cells via induction of apoptosis, 
inhibition of cell cycle progression, and reduction of 
the expression of the MET receptor. The GA ana-
logues tested, despite their modifications, maintain 
strong anticancer properties. It is possible that two 
analogues of GA, 17AEP-GA and 17DMAG, due to 
their properties may prove to be more effective and 
safer chemotherapeutic agents than the currently used 
17AAG, as reported in literature. 
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